Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4026-4030

  Li, Si Yang ^a   Irwin, Scott M ^b   Converse, Paul J ^a   Mdluli, Khisi E ^c   Lenaerts, Anne J ^b   Nuermberger, Eric L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c Global Alliance for TB Drug Development   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; EFFECT SIZE; INCUBATION TIME; LONG TERM CARE; LUNG HOMOGENATE; LUNG LESION; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; TREATMENT DURATION; ANIMAL; BACTERIAL COUNT; BAGG ALBINO MOUSE; C3H MOUSE; LUNG; MICROBIOLOGY; PATHOLOGY; RECURRENT DISEASE; SPECIES DIFFERENCE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; FLUOROQUINOLONES; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; RECURRENCE; SPECIES SPECIFICITY; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84935886018     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00105-15     Document Type: Article

References (28)

1. Grosset J. 1978. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 53:5-12.
2. Grumbach F, Canetti G, Grosset J, Le LM. 1967. Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model. Tubercle 48:11-26. http://dx.doi.org/10.1016/S0041-3879(67)80047-3.
3. Mitchison DA, Chang KC. 2009. Experimental models of tuberculosis: can we trust the mouse? Am J Respir Crit Care Med 180:201-202. http://dx.doi.org/10.1164/rccm.200905-0708ED.
4. Nuermberger E. 2008. Using animal models to develop new treatments for tuberculosis. Semin Respir Crit Care Med 29:542-551. http://dx.doi.org/10.1055/s-0028-1085705.
5. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 205:595-602. http://dx.doi.org/10.1093/infdis/jir786.
6. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56:4331-4340. http://dx.doi.org/10.1128/AAC.00912-12.
7. Driver ER, Ryan GJ, Hoff DR, Irwin SM, Basaraba RJ, Kramnik I, Lenaerts AJ. 2012. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:3181-3195. http://dx.doi.org/10.1128/AAC.00217-12.
8. Irwin SM, Gruppo V, Brooks E, Gilliland J, Scherman M, Reichlen MJ, Leistikow R, Kramnik I, Nuermberger EL, Voskuil MI, Lenaerts AJ. 2014. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 58:4026-4034. http://dx.doi.org/10.1128/AAC.02565-14.
9. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, Kobzik L, Higgins DE, Daly MJ, Bloom BR, Kramnik I. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767-772. http://dx.doi.org/10.1038/nature03419.
10. Ordonez AA, Pokkali S, DeMarco VP, Klunk M, Mease RC, Foss CA, Pomper MG, Jain SK. 2014. Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother 59:642-649. http://dx.doi.org/10.1128/AAC.04180-14.
11. Marzo E, Vilaplana C, Tapia G, Diaz J, Garcia V, Cardona PJ. 2014. Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis. Tuberculosis 94:55-64. http://dx.doi.org/10.1016/j.tube.2013.09.004.
12. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170:1131-1134. http://dx.doi.org/10.1164/rccm.200407-885OC.
13. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169:421-426. http://dx.doi.org/10.1164/rccm.200310-1380OC.
14. De Groote MA, Gilliland JC, Wells CL, Brooks EJ, Woolhiser LK, Gruppo V, Peloquin CA, Orme IM, Lenaerts AJ. 2011. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:1237-1247. http://dx.doi.org/10.1128/AAC.00595-10.
15. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180:273-280. http://dx.doi.org/10.1164/rccm.200901-0078OC.
16. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ. 2014. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371:1577-1587. http://dx.doi.org/10.1056/NEJMoa1407426.
17. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA. 2014. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371:1599-1608. http://dx.doi.org/10.1056/NEJMoa1314210.
18. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174:331-338. http://dx.doi.org/10.1164/rccm.200603-360OC.
19. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189. http://dx.doi.org/10.1016/S0140-6736(09)60333-0.
20. Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P, Balasubramanian R, Selvakumar N, Ponnuraja C, Iliayas AS, Gangadevi NP, Raman B, Baskaran D, Kumar SR, Kumar MM, Mohan V, Ganapathy S, Kumar V, Shanmugam G, Charles N, Sakthivel MR, Jagannath K, Chandrasekar C, Parthasarathy RT, Narayanan PR. 2013. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 8:e67030. http://dx.doi.org/10.1371/journal.pone.0067030.
21. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12:128-138.
22. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 53:4178-4184. http://dx.doi.org/10.1128/AAC.00830-09.
23. Apt A, Kramnik I. 2009. Man and mouse TB: contradictions and solutions. Tuberculosis 89:195-198. http://dx.doi.org/10.1016/j.tube.2009.02.002.
24. Warner DF, Mizrahi V. 2014. Shortening treatment for tuberculosis to basics. N Engl J Med 371:1642-1643. http://dx.doi.org/10.1056/NEJMe1410977.
25. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. 2009. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 180:553-557. http://dx.doi.org/10.1164/rccm.200807-1152OC.
26. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4:e344. http://dx.doi.org/10.1371/journal.pmed.0040344.
27. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53:1314-1319. http://dx.doi.org/10.1128/AAC.01182-08.
28. Lanoix J-P, Lenaerts AJ, Nuermberger EL. 30 March 2015. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech. http://dx.doi.org/10.1242/dmm.019513.